mGluR4 compounds for Parkinson’s disease
This article was originally published in Start Up
Prexton Therapeutics aims to advance the standard of care for Parkinson’s disease by developing a therapeutic that strategically targets metabotropic glutamate receptor 4. It plans to use its lead compound as an add-on therapy to facilitate lower therapeutic doses of L-dopa in order to decrease adverse effects, while maintaining the expected therapeutic level of the treatment.
You may also be interested in...
Parkinson’s disease remains a significant undermet, attractive opportunity for drug developers, including early-stage biotechs. Profiles of MentiNova, Parkure and Prexton Therapeutics.
Quartet Medicine Inc.'s pipeline of novel small-molecule drugs to address chronic pain and inflammation target the tetrahydrobiopterin (BH4) synthesis pathway, a target with genetic and pharmacological links to regulating human disease at the intersection of the peripheral nervous system and the immune system. The start-up thinks its approach has the potential to provide improved efficacy without the side effects associated with existing centrally acting analgesics.
Despite many improvements in the last 25 years, there continue to be serious unmet medical needs in the area of reproductive health. ObsEva SA, a clinical-stage biopharmaceutical company based in Geneva, Switzerland, aims to address some of those needs with novel oral drugs for three highly prevalent reproductive health-related challenges: endometriosis, pre-term labor, and repeated implantation failure in women undergoing in vitro fertilization.